This study is investigating whether the investigational drug IDE196 (darovasertib) in combination with crizotinib is safe and effective in people with a cancer of the eye, uveal melanoma, that has spread (metastasized) to another part of your body. You can find out more about the scientific background of the study in the section describing the study.
Aim of the study
- Investigation of the efficacy of IDE196 with crizotinib compared to standard therapies in the treatment of metastatic uveal melanoma
- Determination of the ideal dose strength of IDE196 in combination with crizotinib
- Further assessments of safety and tolerability and how well the body responds to IDE196 with crizotinib compared to standard treatment
Who can take part?
People over the age of 18 who have been diagnosed with metastatic uveal melanoma and who have not received prior treatment for the spread of the cancer can take part in the study.
Procedure
Your participation in this study will last approximately one to two years from the time you sign this consent form. Additional telephone or clinic follow-up checks will then take place over a period of around two years.
Compensation
Original study name
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)
BASEC number
2023-01759
Sponsors